Figure 2
PAC exhibits potent anti-oral cancer properties through targeting several cancer-promoting pathways. (A) 5 µM of PAC treatment induces cell-cycle arrest, by increasing the expression of cyclin-dependent kinase inhibitors (CDKIs) such as p21, p27, p16 or p53 and Rb, while it inhibits oncogenes such as cyclin D1 or c-Myc on ca9-22 cells. Also, PAC can to reduce DNA damage on oral cancer cells by inhibition of H2A.X protein expression. (B) The effect of PAC on cancer cells is involving specific inhibition of cell proliferation signaling pathways (ERK1/2 phosphorylation, p38, STAT and AKT phosphorylation, NF-κB and Wnt/β-catenin) (n = 3). All Blots for each protein derive from the same experiment and were exposed at same time of phosphor imager exposition.
